Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
395 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Relapsed Multiple Myeloma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Relapsed Multiple Myeloma - Pipeline Review, H2 2014', provides an overview of the Relapsed Multiple Myeloma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Relapsed Multiple Myeloma Overview 9 Therapeutics Development 10 Pipeline Products for Relapsed Multiple Myeloma - Overview 10 Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis 11 Relapsed Multiple Myeloma - Therapeutics under Development by Companies 12 Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 16 Relapsed Multiple Myeloma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Relapsed Multiple Myeloma - Products under Development by Companies 20 Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes 24 Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development 25 Bristol-Myers Squibb Company 25 Johnson & Johnson 26 F. Hoffmann-La Roche Ltd. 27 Sanofi 28 Eli Lilly and Company 29 GlaxoSmithKline plc 30 Biotest AG 31 Piramal Enterprises Limited 32 Prolexys Pharmaceuticals, Inc. 33 Millennium Pharmaceuticals, Inc. 34 Novartis AG 35 Astellas Pharma Inc. 36 Pfizer Inc. 37 Astex Pharmaceuticals, Inc. 38 Exelixis, Inc. 39 Celgene Corporation 40 Onyx Pharmaceuticals, Inc. 41 Immunomedics, Inc. 42 Cellectar Biosciences, Inc. 43 Oncolytics Biotech Inc. 44 Patrys Limited 45 Curis, Inc. 46 Pharmacyclics, Inc. 47 Array BioPharma Inc. 48 MorphoSys AG 49 Sevion Therapeutics, Inc. 50 Threshold Pharmaceuticals, Inc. 51 Synta Pharmaceuticals Corp. 52 Chroma Therapeutics Ltd. 53 Acceleron Pharma, Inc. 54 Altor BioScience Corporation 55 Arno Therapeutics, Inc. 56 Stemline Therapeutics, Inc. 57 Onconova Therapeutics, Inc. 58 Noxxon Pharma AG 59 Acetylon Pharmaceuticals, Inc. 60 Pharma Mar, S.A. 61 AB Science 62 CureTech Ltd. 63 Karyopharm Therapeutics, Inc. 64 AbbVie Inc. 65 Oncopeptides AB 66 Senhwa Biosciences, Inc. 67 Relapsed Multiple Myeloma - Therapeutics Assessment 68 Assessment by Monotherapy Products 68 Assessment by Combination Products 69 Assessment by Target 70 Assessment by Mechanism of Action 75 Assessment by Route of Administration 80 Assessment by Molecule Type 82 Drug Profiles 84 panobinostat - Drug Profile 84 ixazomib citrate - Drug Profile 90 daratumumab - Drug Profile 93 carfilzomib - Drug Profile 96 elotuzumab - Drug Profile 99 plitidepsin - Drug Profile 101 masitinib - Drug Profile 103 bendamustine hydrochloride - Drug Profile 106 ibrutinib - Drug Profile 108 AT-9283 - Drug Profile 113 AT-7519 - Drug Profile 115 PAT-SM6 - Drug Profile 118 vemurafenib - Drug Profile 120 SAR-650984 - Drug Profile 123 filanesib - Drug Profile 124 indatuximab ravtansine - Drug Profile 126 ALT-801 - Drug Profile 128 olaptesed pegol - Drug Profile 130 pidilizumab - Drug Profile 133 PM-00104 - Drug Profile 135 LCL-161 - Drug Profile 136 pomalidomide - Drug Profile 138 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 142 DKN-01 - Drug Profile 144 Melflufen - Drug Profile 146 Recombinant Protein for Cancer - Drug Profile 148 alisertib - Drug Profile 150 linsitinib - Drug Profile 154 milatuzumab - Drug Profile 157 AR-42 - Drug Profile 159 CHR-3996 - Drug Profile 161 PRLX-93936 - Drug Profile 162 oprozomib - Drug Profile 164 cabozantinib s-malate - Drug Profile 166 SNS-01T - Drug Profile 169 ganetespib - Drug Profile 170 SL-401 - Drug Profile 174 TH-302 - Drug Profile 176 P-276 - Drug Profile 183 MOR-202 - Drug Profile 185 palbociclib - Drug Profile 187 marizomib - Drug Profile 190 luminespib - Drug Profile 192 afuresertib hydrochloride - Drug Profile 195 plerixafor - Drug Profile 197 BYL-719 - Drug Profile 199 ricolinostat - Drug Profile 200 LGH-447 - Drug Profile 202 selinexor - Drug Profile 203 Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile 206 tabalumab - Drug Profile 207 daratumumab - Drug Profile 209 BMS-833923 - Drug Profile 212 dalantercept - Drug Profile 214 dasatinib - Drug Profile 216 pelareorep - Drug Profile 219 rigosertib sodium - Drug Profile 224 MLN-0128 - Drug Profile 228 ulocuplumab - Drug Profile 230 veliparib - Drug Profile 231 silmitasertib - Drug Profile 233 quisinostat - Drug Profile 235 afuresertib hydrochloride - Drug Profile 237 CUDC-907 - Drug Profile 239 MV-NIS - Drug Profile 241 venetoclax - Drug Profile 243 LGH-447 - Drug Profile 246 CB-5083 - Drug Profile 247 ACP-196 - Drug Profile 248 GSK-2857916 - Drug Profile 249 I131-CLR1404 - Drug Profile 250 Relapsed Multiple Myeloma - Recent Pipeline Updates 252 Relapsed Multiple Myeloma - Dormant Projects 378 Relapsed Multiple Myeloma - Discontinued Products 379 Relapsed Multiple Myeloma - Product Development Milestones 380 Featured News & Press Releases 380 Appendix 389 Methodology 389 Coverage 389 Secondary Research 389 Primary Research 389 Expert Panel Validation 389 Contact Us 390 Disclaimer 390
List of Tables Number of Products under Development for Relapsed Multiple Myeloma, H2 2014 15 Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2014 16 Number of Products under Development by Companies, H2 2014 18 Number of Products under Development by Companies, H2 2014 (Contd..1) 19 Number of Products under Development by Companies, H2 2014 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2014 21 Comparative Analysis by Late Stage Development, H2 2014 22 Comparative Analysis by Clinical Stage Development, H2 2014 23 Comparative Analysis by Early Stage Development, H2 2014 24 Products under Development by Companies, H2 2014 25 Products under Development by Companies, H2 2014 (Contd..1) 26 Products under Development by Companies, H2 2014 (Contd..2) 27 Products under Development by Companies, H2 2014 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2014 29 Relapsed Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2014 30 Relapsed Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2014 31 Relapsed Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 32 Relapsed Multiple Myeloma - Pipeline by Sanofi, H2 2014 33 Relapsed Multiple Myeloma - Pipeline by Eli Lilly and Company, H2 2014 34 Relapsed Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H2 2014 35 Relapsed Multiple Myeloma - Pipeline by Biotest AG, H2 2014 36 Relapsed Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 39 Relapsed Multiple Myeloma - Pipeline by Novartis AG, H2 2014 40 Relapsed Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2014 41 Relapsed Multiple Myeloma - Pipeline by Pfizer Inc., H2 2014 42 Relapsed Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 43 Relapsed Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2014 44 Relapsed Multiple Myeloma - Pipeline by Celgene Corporation, H2 2014 45 Relapsed Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 46 Relapsed Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2014 47 Relapsed Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H2 2014 48 Relapsed Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2014 49 Relapsed Multiple Myeloma - Pipeline by Patrys Limited, H2 2014 50 Relapsed Multiple Myeloma - Pipeline by Curis, Inc., H2 2014 51 Relapsed Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H2 2014 52 Relapsed Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2014 53 Relapsed Multiple Myeloma - Pipeline by MorphoSys AG., H2 2014 54 Relapsed Multiple Myeloma - Pipeline by Sevion Therapeutics, Inc., H2 2014 55 Relapsed Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 56 Relapsed Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2014 57 Relapsed Multiple Myeloma - Pipeline by Chroma Therapeutics Ltd., H2 2014 58 Relapsed Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H2 2014 59 Relapsed Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2014 60 Relapsed Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2014 61 Relapsed Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2014 62 Relapsed Multiple Myeloma - Pipeline by Onconova Therapeutics, Inc., H2 2014 63 Relapsed Multiple Myeloma - Pipeline by Noxxon Pharma AG, H2 2014 64 Relapsed Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 65 Relapsed Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2014 66 Relapsed Multiple Myeloma - Pipeline by AB Science, H2 2014 67 Relapsed Multiple Myeloma - Pipeline by CureTech Ltd., H2 2014 68 Relapsed Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 69 Relapsed Multiple Myeloma - Pipeline by AbbVie Inc., H2 2014 70 Relapsed Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2014 71 Relapsed Multiple Myeloma - Pipeline by Senhwa Biosciences, Inc., H2 2014 72 Assessment by Monotherapy Products, H2 2014 73 Assessment by Combination Products, H2 2014 74 Number of Products by Stage and Target, H2 2014 77 Number of Products by Stage and Mechanism of Action, H2 2014 82 Number of Products by Stage and Route of Administration, H2 2014 86 Number of Products by Stage and Molecule Type, H2 2014 88 Relapsed Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2014 257 Relapsed Multiple Myeloma - Dormant Projects, H2 2014 383 Relapsed Multiple Myeloma - Discontinued Products, H2 2014 384
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
